News

Researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.

Researchers have found that greater gut microbial diversity in patients with metastatic kidney cancer is linked to a better treatment outcome, for patients on FDA-approved immunotherapy regimens.

A new database of 40 breast cancer cell lines aims to help researchers deepen their understanding of these cell lines and speed up the development of new gene-targeted therapies.

In a study funded by the National Institutes of Health, researchers showed that experimental drugs designed to lower the body’s natural production of alpha-ketoglutarate extended the lives of mice with brain tumors by slowing the growth of the cancer cells.

Alternative carrier-free systems, known as nanoprodrugs (NPD), show immense promise for cancer treatment. Now, researchers have carried out a study on the dynamics of SN-38 NPDs inside cancer cells, looking specifically at their internalization rate, intracellular localization and degradation, as well as their therapeutic efficiency.

A new study suggests that since the typically robust immune systems of young, female patients are better at getting rid of cancer cells, the cells left behind are not as readily visible to the immune system to begin with, meaning some types of immunotherapy are ineffective.

Analysis of the genomes of 28,000 tumors from 66 types of cancer has led to the identification of 568 cancer driver genes.

A tumor test could help to identify ovarian cancer patients with predicted poor survival and pave the way towards personalized treatment, according to a new study.

In a study published in Cell Metabolism, Harvard Medical School researchers identified a critical role of the enzyme, prolyl hydroxylase 3 (PHD3), in sensing nutrient availability and regulating the ability of muscle cells to break down fats.

Researchers have developed a microfluidic OvCa-Chip to enable them to investigate the biological processes between ovarian tumors and platelets.